PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting
Rattachement africain : es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
PURPOSE: This study aims to assess the effectiveness and safety of combining the Preserflo™ MicroShunt implant (MicroShunt) with a simultaneous Ologen™ implant in patients with glaucoma. METHODS: We conducted a retrospective study on consecutive patients with medically uncontrolled glaucoma who underwent MicroShunt + Ologen implantation as a standalone procedure or in combination with phacoemulsification (combined procedure). Success was defined as achieving an intraocular pressure (IOP) of 6-15 mmHg at 18 months post surgery, with a preoperative IOP reduction of at least 20%, and without (complete success) or with (qualified success) the need for antiglaucoma medications. The primary endpoint was the success rate. RESULTS: Forty-eight eyes from 47 patients were included, with 28 eyes (58.3%) undergoing the standalone procedure and 20 eyes (41.7%) undergoing the combined procedure. Overall, there was a significant reduction in preoperative IOP from 19.7 ± 5.8 mmHg to 11.4 ± 2.6 mmHg at 18 months ( P < 0.0001). In the standalone procedure group, preoperative IOP decreased from 21.5 ± 5.2 mmHg to 11.7 ± 2.5 mmHg ( P < 0.0001), and in the combined procedure group, preoperative IOP decreased from 17.1 ± 5.8 mmHg to 10.9 ± 2.7 mmHg ( P = 0.0002), with no significant difference between the two groups regarding final IOP. The mean number of antiglaucoma medications significantly decreased from 3.2 ± 1.1 to 0.3 ± 0.7 in the overall study population ( P < 0.0001). At 18 months, 40 eyes (83.3%) were classified as successful. Regarding safety, out of the total number of eyes, two (4.2%) experienced choroidal detachment without visual impairment, two (4.2%) had transient hyphema, one (2.1%) showed reactivation of a corneal herpetic ulcer, one (2.1%) had diplopia, and one (2.1%) exhibited a shallow anterior chamber during the first week. CONCLUSION: The combination of Ologen™ and Preserflo™ MicroShunt, either alone or in conjunction with phacoemulsification, demonstrated a favorable profile in terms of IOP reduction and safety.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- PreserfloTM MicroShunt implantation combined with OlogenTM in primary and secondary glaucoma patients in a clinical setting
- Date Crossref
- 26/12/2023
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hospital Virgen de la Luz Glaucoma Department pays non établi dans la noticeÉtablissement de santé
-
Universidad Complutense de Madrid pays non établi dans la noticeUniversité ou école supérieure
-
Hospital Clínico San Carlos pays non établi dans la noticeÉtablissement de santé
-
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos pays non établi dans la noticeÉtablissement de santé
-
Universitat Autònoma de Barcelona pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine Department of Immunology pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Medicine Department of Ophthalmology and ORL pays non établi dans la noticeUniversité ou école supérieure
-
Glaucoma Specialist pays non établi dans la noticeInstitution
-
Departament of Ophthalmology pays non établi dans la noticeInstitution
-
Autonoma University of Barcelona Department of Ophthalmology pays non établi dans la noticeUniversité ou école supérieure
Glaucoma Department — Hospital Virgen de la Luz, Universidad Complutense de Madrid et Hospital Clínico San Carlos, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.